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Background. BK virus nephritis (BKVN) has emerged as an
important cause of renal transplant failure. Quantified analysis
of its timing and clinical course is generally lacking. We have
thus quantified the timing, risk factors, evolution of renal func-
tion, and transplant graft outcome in renal transplant recipients
with BKVN from our center.
Methods. A total of 41 cases of BKVN were diagnosed in 1001
renal and renal/pancreas transplant recipients. There were 2
groups: group I (N = 16), with diagnosis based on renal biopsy
alone from January 1996 to August 2001, and group II (N =
25), with diagnosis based on quantitative blood BKV-PCR and
biopsy from September 2001 to December 2003. The demo-
graphics, the clinical course, immunosuppressive therapy, re-
nal function, and graft outcome were quantified. Donor, re-
cipient, and transplant risk variables were studied using a uni-
variate analysis. Actuarial graft survival was calculated. An im-
munosuppressive scale created to evaluate the degree of im-
munosuppression in these patients and its reduction after the
diagnosis of BKVN.
Results. The median time from transplant to BKVN diagno-
sis was 318 days (range 48–1356). The actuarial graft survival
in patients with BKVN at 6 months, 1, 3, and 5 years was 97%,
90%, 58%, and 47%. The corresponding values for those with-
out BKVN were 94%, 92%, 83%, and 76%, respectively, P <
0.001. Graft loss occurred in 46% of patients. The rate of decline
of renal function in group II (N = 25) patients in the 4 months
preceding BKVN was rapid (4.8 mL/min/month) and this de-
clined to 0.7 mL/min/month at 3 months’ post-BKVN diagnosis,
P = 0.004. In those who recovered, the time to stabilization of
renal function was a median of 112 days. The immunosuppres-
sive scale score was 7 units at the time of diagnosis of BKVN
and decreased to 3.5 units at 3 months’ post-BKVN. Reduction
in the dose of calcineurin inhibitors but not the overall reduc-
tion in dose of immunosuppression correlated with recovery of
renal function in these patients.
Conclusion. BKVN is a relatively late complication of renal
transplantation. Despite reduction in immunosuppression, graft
loss occurred in 46% of patients. There was a steep decline in
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renal function in months preceding the diagnosis of BKVN, and
reduction in calcineurin inhibitor dose, but not overall immuno-
suppression, correlated with stabilization of renal function.
BK virus nephritis (BKVN) is now increasingly recog-
nized as an important cause of renal graft loss [1, 2]. The
emergence of BKVN coincides with decreasing acute re-
jection rates and use of potent immunosuppressants [3].
Both its diagnosis and its treatment have been hampered
by lack of awareness, nonavailability of diagnostic tools,
and close resemblance of BKVN to acute rejection on
histologic evaluation. Increasing awareness of this condi-
tion, use of SV–40 stain, and the availability of BK viral
load measurement by reverse transcription-polymerase
chain reaction (RT-PCR), have improved diagnosis [4].
However, there is still a substantial graft loss rate of up
to 50% [5]. Although cidofovir and leflunomide have
been used with anecdotal success, reliable antiviral ther-
apy does not exist [6]. Reduction in immunosuppression
remains a common approach in treating BKVN.
While a number of studies have focused on diagnosis
and management of BKVN [7–10], few have examined
the risk factors and clinical course of this disease [11–14].
In addition, quantification of immunosuppressive ther-
apy at the time of BKVN diagnosis, its reduction, and
analysis of its effect on BKVN has never been attempted.
In this retrospective single-center study, we quantified the
timing, clinical course, risk factors, outcome, and effec-
tiveness of immunosuppressive dose reduction in BKVN
in renal transplant recipients.
METHODS
Patient population and diagnosis of BKVN
A total of 1001 renal and renal/pancreas transplants
were performed at the Medical College of Wisconsin be-
tween January 1996 and December 2003, with follow-
up through September 2004. During this time period 41
cases of BKVN were diagnosed. The prospectively main-
tained medical records were used for this analysis, with
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permission by the Institutional Review Board of the Med-
ical College of Wisconsin. Two groups were identified:
group I (N = 16), who were diagnosed with BKVN from
January 1996 to August 2001, and group II (N = 25), who
were from September 2001 to December 2003. Group I
cases were diagnosed by renal allograft biopsy alone, and
group II cases were diagnosed using the combination of
blood BKV-PCR quantification and typical renal histo-
logic findings. The indications for renal biopsy included
rise in serum creatinine by 15% above baseline. Re-
nal histology was evaluated both by a nephropathologist
and a transplant nephrologist. Diagnosis of BKVN was
suspected in biopsies showing focal interstitial mononu-
clear inflammatory cell infiltrates, presence of plasma
cells, necrotic tubular epithelium, and presence of ho-
mogenous intranuclear inclusion bodies. The diagnosis
of BKVN was confirmed using the SV–40 stain using im-
munoperoxidase method.
Risk factors and renal function
Risk factors for the occurrence of BKVN were eval-
uated for donor, recipient, and transplant risk variables.
Renal function was tested as serum creatinine; evolution
of renal function was portrayed as 100/s creatinine, and
creatinine clearance was calculated using the Cockcroft
and Gault formula.
Clinical management and follow up of BKVN cases
We systematically reviewed the group II cases (N = 25)
of BKVN diagnosed after August 2001, which is when
we began systematic use of blood PCR testing. These
cases were managed by reduction in immunosuppres-
sion, as guided by individual characteristics and tolerance.
The immunosuppression was reduced by about 40% on
an empiric basis. Periodic evaluation of renal function
and blood BKV DNA loads were estimated using PCR
monthly until the copies were negative or the graft was
lost.
Immunosuppression scale for BKVN
Because the occurrence of BKVN is thought to be
linked to intensity of immunosuppression, we used dose
reduction and/or change from triple to double im-
munosuppressive therapy in managing these cases. Our
approach to reduction of immunosuppression in these
patients was variable depending on individual patients.
Thus, for analysis of these cases, we devised an empiric
immunosuppressive unit scale, which was then applied
retrospectively to the evolution of all group II cases.
We assigned 1 unit of immunosuppression for each of
the following doses of immunosuppressive medications:
cyclosporine 100 mg, tacrolimus 2 mg, mycophenolate
mofetil 500 mg, prednisone 5 mg, sirolimus 2 mg, and
Table 1. A novel scale developed to quantify Immunosuppressive
medication reduction in patients who developed BKVN. One unit of
immunosuppression was assigned to the corresponding doses of agents
Immunosuppression units Agents Unit dose mg/day
1 Prednisone 5
1 Azathioprine 100
1 Cyclosporine 100
1 Tacrolimus 2
1 Mycophenolate mofetil 500
1 Sirolimus 2
azathioprine 100 mg (Table 1). We thus quantified the
immunosuppression in units/day at the time of diagno-
sis of BKVN, at 1 month, and 3 months’ postdiagnosis of
BKVN. Importantly, this scale was not used in the clinical
management of patients, but was devised specifically for
the uniform analysis of the group II cohort.
Statistical analysis
Statistical analysis was performed using InStat
(GraphPad software; San Diego, CA, USA). Univari-
ate analysis was used to estimate the risk factors for
the development of BKVN. Actuarial graft survival dif-
ferences were calculated using log-rank test. Kidney
function was calculated using the Cockcroft and Gault
formula. Multiple regression was used to test influences
on loss of renal function. Chi-square test was used to test
statistical significance of dichotomous variables, and a P
value of < 0.05 was considered significant.
RESULTS
The demographics for the entire group and risk factors
for the occurrence of BKVN are shown in Table 2 (mean
± SD). The mean age at the time of diagnosis was 44
(range 26–70 years) and 60% of the patients were men.
Twenty-four (58%) of the patients were Caucasians, 15
(36%) were African Americans, and 2 (5%) were oth-
ers (Hispanics or Asian). A total of 22 (54%) had re-
ceived renal grafts and 5 renal/pancreas (12%) from de-
ceased donors and the remaining 14 (34%) from living
donors. The majority of the patients were on a combi-
nation of tacrolimus, mycophenolate mofetil, and pred-
nisone. There were no demographic, pretransplant, or
posttransplant risk factors identified among the 41 pa-
tients with BKVN (Table 2).
The incidence rate of BKVN for the 2 groups was
16/687 (2.3%) for group I and 25/314 (7.9%) for group
II (Overall 41/1001 = 4%). Thus, there was an increase in
the incidence of BKVN in the 2001 to 2003 time frame.
The median time to diagnosis of BKVN was 318 days
(range 48–1356 days). There were no differences in time
to BKVN diagnosis according to race, sex, type of trans-
plant, or between group I and II cases. Overall renal graft
failure occurred in 19 (46%) cases, and the actuarial renal
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Table 2. Demographics and risk factorsa for the development of
BKVN
Total BKVN yes BKVN no
(N = 1001) (N = 41) (N = 960) P
Age at transplant years 44 ± 12.1 47 ± 13.7 0.22
(mean)
Sex (M/F) N 29/12 572/388 0.2
Race (W/B/other) N 24/15/2 664/214/82 0.09
Organ source (deceased vs. 27/14 564/396 0.8
living donor) N
Renal/pancreas Tx N 5 112 0.8
CIT hours (mean) 10.6 ± 8.7 14 ± 10.3 0.05
HLA match—mean 2.31 ± 1.8 2.71 ± 1.9 0.22
PRA—mean 3.19 ± 15 6.65 ± 20 0.39
CMV (D+R−) N 9 316 0.19
Donor age years (mean) 42 ± 13.8 37 ± 16.5 0.08
Abbreviations are BKVN, BKV nephritis; W, white; B, black; CIT, cold
ischemia time; Tx, transplant; HLA, human leukocyte antigen; PRA, panel
reactive antibody; CMV, cytomegalovirus; D, donor; R, recipient.
aUnivariate analyses was performed for evaluating risk factors.
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Fig. 1. Life table graph showing actuarial renal transplant survival in
all 41 cases with BKVN at our center. There is clear-cut reduction in
graft survival in subjects with BKVN.
graft survival for these patients with documented BKVN
was lower than for the unaffected renal transplant recip-
ients (Fig. 1). The 6-month, 1, 2, 3, and 5 years’ post-
transplant actuarial renal graft survival for those who
had BKVN was 97%, 90%, 58%, and 47%, respectively.
The corresponding values for the rest of the population
were 94%, 92%, 83%, and 76%, respectively (P < 0.001).
Among group I cases there were 10 graft losses out of 16
cases, compared to 9 out of the 25 cases in group II (P =
0.11).
The renal function was calculated using the Cockcroft-
Gault formula for creatinine clearance, at time of diag-
nosis of BKVN, at 4 months before diagnosis of BKVN,
and at the most recent follow-up time for all group II
cases. The median rate of decline of renal function in
the 4 months before the diagnosis of BKVN was 4.8
mL/min/month. The median duration of follow-up was
8 months (range 1 to 34 months). In this group of pa-
tients the rate of decline slowed to 0.7 mL/min/month
(P = 0.004) (Fig. 2). Renal transplant loss was more likely
when serum creatinine at diagnosis of BKVN was 2.2
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Fig. 2. Comparison of the median decline in creatinine clearance for
the four months before the diagnosis of BKVN and during subsequent
follow-up after adjustment in immunosuppressive therapy in the 25
cases of group II.
mg/dL or higher (P < 0.01). The evolution of renal func-
tion, using 100/serum creatinine for 2 cases with BKVN is
shown in Figure 3. Figure 3A illustrates a case from group
I, in which immunosuppression was not decreased, and
subsequent progression of renal disease. Figure 3B shows
a case from group II, with stabilization of function in as-
sociation with reduction in immunosuppression.
The median immunosuppression units at diagnosis of
BKVN were 7 (range 3 to 18). This decreased to a me-
dian value of 4.25 units (range 2 to 7) at 3 months later,
a change of ∼ 40%. The median units for calcineurin
inhibitors alone were 3.5 at diagnosis, and this was de-
creased to 1 by 3 months, a change of ∼ 70%. The unit
change in total immunosuppression did not correlate with
changes in creatinine clearance, but the change in units
of calcineurin inhibitors (CNI) correlated with slowing
in the rate of loss of renal function (P = 0.02) (Fig. 4).
Despite the decrease in immunosuppression, 9/25 (36%)
of these patients lost their graft. Only 1 patient received
treatment with leflunamide. In cases of BKVN in which
there is stabilization or recovery of renal function, this
is delayed and can be weeks to months after diagnosis.
In our patients, we evaluated time to stabilization of re-
nal function as being from time to diagnosis to the date
when there were 2 successive stable or increasing values
of 100/s creatinine. The median time to stabilization in
those with a functioning graft in group II cases was 112
days.
DISCUSSION
There has been a progressive increase in the prevalence
of BKVN in renal transplant recipients. Use of potent im-
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Fig. 3. (A) Time series plot of the evolution of renal function using
100/serum creatinine illustrating progressive renal failure in a case with
BKVN in whom immunosuppression was unchanged. (B) Evolution
of renal function using 100/serum creatinine illustrating stabilization
of renal function in association with reduction in immunosuppressive
therapy.
munosuppressive agents has been thought to be a key
factor that predisposes to BKVN [2]. Thus, reduction
in immunosuppression has been adopted as a common
treatment for BKVN [7]. Other therapies such as lefluno-
mide and cidofovir have been attempted in an uncon-
trolled fashion with varied success [15]. A major empha-
sis has been made on diagnosis using molecular tech-
niques, especially for BKV DNA in the blood [16].
This has enabled documentation of disappearance of
viremia with reduction in immunosuppression therapy
[17]. However, timing and risk factors for the develop-
ment of infection have not been clearly defined. In ad-
dition, quantification of immunosuppressive therapy at
the time of diagnosis and evaluating outcome using evo-
IS
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Fig. 4. Overall and CNI immunosuppressive scale (IS) units at the time
of diagnosis of BKVN and three months’ postdiagnosis. The reduction
in overall IS units did not correlate with slowing of the loss of renal
function, but the reduction in CNI units did.
lution of renal function has never been studied. This
study evaluated these important parameters in a single
center.
In the current series, the diagnosis of BKVN occurred
at a median time of 11 months after transplantation. This
is not dissimilar to the 13-month interval found by Ramos
et al [18]. This illustrates that this condition is unlike
acute rejection, which is most common within the first
6 months after transplantation. There were no obvious
risk variables identified in the larger group of 41 cases.
Some have postulated a double-hit hypothesis, in which
a combination of preservation injury and immunologic
damage predisposes renal grafts to BKVN [19]. How-
ever, in our series there was no negative impact of cold is-
chemic time, as well as donor source (living vs. deceased),
in influencing the development of BKVN. It is possible
that with a greater number of cases, a transplant vari-
able or risk factor for BKVN could have been statistically
significant. BKVN predominates in renal transplant re-
cipients compared to other solid organ transplants, such
as liver or heart recipients. This may be due to alloim-
mune activation in the renal graft predisposing to the
development of BKVN, and this has been shown in an
animal model [19]. Nonetheless, we did not see any im-
pact of HLA mismatches or PRA levels on BKVN. Ab-
sence of obvious risk factors in our study may perhaps
be secondary to lower prevalence of positive cases (4%),
which were compared to a large number of negative cases
(96%).
Our series also clearly shows the negative impact of
this condition on renal graft survival (Fig. 1). This has
been acknowledged in other series [20]. Inability to distin-
guish from acute rejection in early years and inadvertent
overuse of immunosuppression resulted in irreversible
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graft failure, as shown in the case in Figure 3A. In ad-
dition, our earlier experience showed substantial graft
failure in 10 out of 16 (62%) cases. However, in recent
years graft failure rates have decreased to 9 out of 25
cases (36%), P = 0.11. Given the small numbers of pa-
tients in our study this could represent a beta error. We
believe that the improvement corresponds to our increas-
ing awareness of BKVN and to our use of blood PCR for
screening and diagnosis.
The current study illustrates a case (Fig. 3B) in which
stabilization of renal function occurred with reduction
in immunosuppressive therapy. We have quantified this
evolution for the entire series by systematic analysis of
the most recent 25 cases of BKVN. There was a loss of
creatinine clearance of 4.8/mL/min/month for a period
of 4 months prior to the diagnosis of BKVN. This stabi-
lized to a mean renal function loss of 0.7 mL/min/month
during subsequent follow-up (Fig. 4). Using reduction of
immunosuppression alone has been successful in manag-
ing the majority (16/25) of cases. Irreversible renal graft
failure occurring in the remaining 9 cases either may be
due to aggressive disease either due to lack of humoral
and or cellular immunity in the recipient, intensity and
early onset of acute BKVN, or possible subacute rejec-
tion with postreduction in immunosuppressive therapy.
Only 3/25 patients in group II developed frank rejec-
tion (biopsy proven), and 2/3 of these patients lost the
graft.
The improvement and stabilization of renal function
seen in the BKVN cases managed by reduction in im-
munosuppression is unlikely to be only due to reduction
in calcineurin inhibitor since that effect would be imme-
diate. The slow improvement in renal function suggests
gradual decrease in renal parenchymal inflammation as-
sociated with clearance of the virus and resolution of
nephritis.
The inability to identify an immune marker for suf-
ficient yet nontoxic immunosuppression remains a ma-
jor problem in preventing complications such as BKVN.
Our immunosuppression unit scale represents a simple
method to quantify the many combinations and doses
of immunosuppressive drugs. Even though such an arbi-
trary scale has potential pitfalls, such an approach may
be of value in evaluating a single disease such as BKVN
before and after reduction in immunosuppression. It is
worth noting that our scale suggested that changes in
CNI units, and not overall immunosuppression units, cor-
related with the slowing of loss of renal function in our
cases. It is difficult to discriminate immunosuppressive
effect and nonimmunosuppressive nephrotoxicity effects
of CNI inhibitor. However, the reversal of CNI nephro-
toxicity was not immediate, as might be expected from
mere vasoconstrictive effects. It is possible that a graded
assessment of histologic findings may have permitted bet-
ter prediction of outcome [21].
CONCLUSION
BK virus nephritis is an increasing problem occurring
many months after renal transplantation. BKVN pro-
gresses rapidly, is associated with substantial risk for renal
graft loss, and there are no identifiable risk factors leading
to the occurrence of this disease. Early prompt diagno-
sis and avoidance of excessive immunosuppression can
stabilize this disease in the majority of cases. Stabiliza-
tion of function may take up to 3 months after a change
in immunosuppressive therapy. The immunosuppressive
scale we developed may have benefit in evaluating and
managing BKVN.
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